| Tu, John H |
NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). |
|
|
| Active, not recruiting | 3 | 186 | US | Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Biofrontera Bioscience GmbH | Superficial Basal Cell Carcinoma | 03/24 | 02/29 | | |
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp |
|
|
| Recruiting | 3 | 165 | US | BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp | Biofrontera Bioscience GmbH | Actinic Keratoses | 09/25 | 06/26 | | |
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) |
|
|
| Completed | 2 | 199 | US | NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel | NFlection Therapeutics, Inc. | Cutaneous Neurofibroma, Neurofibromatosis 1 | 10/23 | 10/23 | | |
NCT05080764: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults |
|
|
| Recruiting | 2 | 126 | US | 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Biofrontera Bioscience GmbH | Acne Vulgaris | 02/25 | 02/25 | | |
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp |
|
|
| Completed | 1 | 112 | US | BF-200 ALA and red light LED lamp | Biofrontera Bioscience GmbH | Actinic Keratosis, Keratosis, Actinic, Keratosis | 04/23 | 04/23 | | |
| Dennis, Patrick |
| Completed | 4 | 580 | US | Galcanezumab, LY2951742, Rimegepant, Placebo | Eli Lilly and Company | Migraine, Episodic Migraine | 05/23 | 05/23 | | |
|
| Completed | 3 | 275 | US | Digital ACT, Digital Symptom Tracker | Swing Therapeutics, Inc. | Fibromyalgia | 05/23 | 05/23 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection |
|
|
| Completed | 2 | 63 | US | TNX-102 SL, Placebo SL Tablet | Tonix Pharmaceuticals, Inc. | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 07/23 | 07/23 | | |
NCT06282458: Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt |
|
|
| Active, not recruiting | 2 | 150 | US | Enobosarm, Semaglutide, Wegovy | Veru Inc. | Muscle Loss, Obesity | 12/24 | 04/25 | | |
| Recruiting | 2 | 1380 | NA | 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A | Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc | Influenza | 05/25 | 12/25 | | |
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity |
|
|
| Recruiting | 2 | 350 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity | 01/26 | 10/26 | | |
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain |
|
|
| Recruiting | 2 | 10000 | US | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo | Eli Lilly and Company | Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain | 04/27 | 04/27 | | |
| Bruce, Alison |
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | US, RoW | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 10/24 | 04/25 | | |
| Scuderi, Heather |
RISE 3, NCT06309966: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy |
|
|
| Recruiting | 2/3 | 390 | Europe, US, RoW | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Focal Epilepsy | 08/25 | 09/25 | | |
SHINE, NCT06425159: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures |
|
|
| Recruiting | 2/3 | 242 | Europe, US, RoW | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Generalized Epilepsy | 07/26 | 07/27 | | |
| Bryant, Danielle |
| Active, not recruiting | 3 | 1882 | Europe, Canada, Japan, US, RoW | Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen | Novartis Pharmaceuticals | Relapsing Multiple Sclerosis | 12/27 | 09/28 | | |
|
RISE 3, NCT06309966: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy |
|
|
| Recruiting | 2/3 | 390 | Europe, US, RoW | BHV-7000, Placebo | Biohaven Therapeutics Ltd. | Focal Epilepsy | 08/25 | 09/25 | | |
| Thorla, Ira |
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | US, RoW | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 10/24 | 04/25 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
NCT04911751: A Study to Investigate Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis |
|
|
| Active, not recruiting | 2 | 80 | US, RoW | KBL697 | KoBioLabs | Psoriatic Plaque | 11/23 | 03/24 | | |
NCT05080764: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults |
|
|
| Recruiting | 2 | 126 | US | 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Biofrontera Bioscience GmbH | Acne Vulgaris | 02/25 | 02/25 | | |
NCT06309355: Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis |
|
|
| Recruiting | 2 | 36 | US | YR001 ointment, Placebo | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | Atopic Dermatitis | 01/25 | 06/25 | | |
NCT06603220: A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria |
|
|
| Recruiting | 2 | 30 | US | Oral EVO756 | Evommune, Inc. | Chronic Inducible Urticaria | 03/25 | 04/25 | | |
| Sanders, Taylor |
| Completed | 4 | 580 | US | Galcanezumab, LY2951742, Rimegepant, Placebo | Eli Lilly and Company | Migraine, Episodic Migraine | 05/23 | 05/23 | | |
|
| Completed | 3 | 275 | US | Digital ACT, Digital Symptom Tracker | Swing Therapeutics, Inc. | Fibromyalgia | 05/23 | 05/23 | | |
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection |
|
|
| Completed | 2 | 63 | US | TNX-102 SL, Placebo SL Tablet | Tonix Pharmaceuticals, Inc. | Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID | 07/23 | 07/23 | | |
| Recruiting | 2 | 1380 | NA | 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A | Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc | Influenza | 05/25 | 12/25 | | |
| Bolton, Brittany |
NCT05603754: A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES) |
|
|
| Completed | 3 | 496 | US | Lorecivivint, SM04690, Placebo, Vehicle | Biosplice Therapeutics, Inc., NBCD A/S | Knee Osteoarthritis | 02/24 | 02/24 | | |
| Recruiting | 2 | 1380 | NA | 3.75 µg H5N8 antigen plus full dose AS03A, 7.5 µg H5N8 antigen plus full dose AS03A, 15 µg H5N8 antigen plus full dose AS03A, 3.75 µg H5N8 antigen plus half dose AS03A, 7.5 µg H5N8 antigen plus half dose AS03A, 15 µg H5N8 antigen plus half dose AS03A, 3.75 µg H5N8 antigen plus MF59, 7.5 µg H5N8 antigen plus MF59, 15 µg H5N8 antigen plus MF59, 3.75 µg H5N1 antigen plus full dose AS03A, 7.5 µg H5N1 antigen plus full dose AS03A, 15 µg H5N1 antigen plus full dose AS03A | Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., ICON plc | Influenza | 05/25 | 12/25 | | |
| Kingsley, Hilary |
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis |
|
|
| Terminated | 2 | 229 | Canada, US | RPT193, Placebo | RAPT Therapeutics, Inc. | Atopic Dermatitis | 05/24 | 05/24 | | |
